$MCK (McKesson Corporation)

$MCK {{ '2015-07-29T20:41:40+0000' | timeago}} • Announcement

$MCK 1Q16 PR: Revenues for quarter were $47,546MM, up 9% compared to $43,476MM in 1Q15. Net income attributable to McKesson Corporation increased 43% to $576MM compared to $403MM in 1Q15. In addition, Celesio announced plans to acquire Sainsbury’s UK-based pharmacy operations.

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$MCK {{ '2017-10-04T13:44:29+0000' | timeago}} • Announcement

McKesson Ventures, a unit of $MCK, has appointed Carrie Hurwitz as Principal. In addition, the company named Irem Mertol its Director. Most recently, Williams served as VP of Strategy and Business Development at Omada Health. Mertol comes to McKesson from Burd Health, where she held various leadership positions.

$MDRX {{ '2017-08-03T20:38:50+0000' | timeago}} • Announcement

Healthcare technology provider $MDRX has agreed to acquire the enterprise information solutions business of $MCK for $185MM in cash. The transaction is expected to close early in the fourth quarter of calendar year 2017. The company plans to fund the transaction through its existing secured credit facilities and cash balances.

$MCK {{ '2017-07-26T17:19:04+0000' | timeago}} • Announcement

$MCK said all board members were re-elected at the annual stockholders’ meeting. Also, all board vote recommendations were upheld, except the advisory vote on executive compensation. The Compensation Committee will review of the current executive compensation plan and consider implementing changes so as to align incentives and shareholder value.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$MCK {{ '2017-05-24T20:45:05+0000' | timeago}} • Announcement

The Board of Directors of $MCK declared a regular dividend of $0.28 per share on common stock. The dividend will be payable on July 3, 2017, to stockholders of record on June 5, 2017.

$MCK {{ '2017-05-18T22:30:24+0000' | timeago}} • Webcast

$MCK stated that on the buy side for generics, the company is seeing a deflation going forward. However, the company added that deflation is not a big factor that plays into the way its economics or P&L operates.

$MCK {{ '2017-05-18T21:05:10+0000' | timeago}} • Announcement

During 4Q17, $MCK's Distribution Solution revenues rose 5% YoY to $48.2Bil. Revenues of North America pharmaceutical distribution and services revenues were $40.6Bil, up 5%. International pharmaceutical distribution and services revenues were $6.1Bil and Medical-Surgical distribution and services revenues were $1.6Bil.

$MCK {{ '2017-05-18T21:01:30+0000' | timeago}} • Announcement

$MCK reported an increase in 4Q17 profit, due to a pre-tax gain of $3.9Bil related to the previously announced creation of the Change Healthcare joint venture. Net income rose to $3.6Bil, or $16.95 per share, compared to $431MM, or $1.97 per share during 4Q16. Revenues rose 4% YoY to $46.7Bil during the quarter.

$MCK {{ '2017-04-04T14:57:34+0000' | timeago}} • Announcement

$MCK completed the previously announced acquisition of CoverMyMeds LLC. CoverMyMeds is a player in electronic prior authorization (ePA) solutions.

$MCK {{ '2017-03-02T17:03:35+0000' | timeago}} • Announcement

$MCK lifted FY17 EPS from continuing operations guidance to $20.35-22.50 from $9.80-10.30, while lowering adjusted EPS outlook to $12.45-12.75 from $12.60-12.90. $MCK will record its share of a one-time, non-cash reduction to the carrying value of its deferred revenue balance. This will lower earnings in FY18 by about $140-170MM.

$MCK {{ '2017-03-02T16:59:04+0000' | timeago}} • Announcement

In 4Q17, $MCK expects to record a pre-tax gain of about $2.9-3.5Bil, which includes $1.25Bil in cash receipts, and associated non-cash income tax expense of about $0.5-0.8Bil, both of which will be excluded from adjusted earnings. As a result of net gain, $MCK will add about $10.70-12.35 in EPS from continuing operations.

$MCK {{ '2017-01-26T11:50:05+0000' | timeago}} • Announcement

$MCK's BoD declared a regular dividend of 28 cents per share on common stock. The dividend will be payable on April 3, 2017, to stockholders of record on March 1, 2017.

$MCK {{ '2017-01-25T23:00:05+0000' | timeago}} • Announcement

On Jan. 24, 2017 $MCK entered into an agreement to acquire CoverMyMeds for approx. $1.1Bil, or $0.9Bil net of incremental cash tax benefits. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the first half of FY18.

$MCK {{ '2017-01-25T22:57:39+0000' | timeago}} • Announcement

During 3Q17, $MCK's Distribution Solutions reported 5% growth in its revenues to $49.4MM. North America pharmaceutical distribution and services revenues rose 5% to $41.7Bil and International pharmaceutical distribution and services revenues were $6.2Bil for the quarter, up 3%.

$MCK {{ '2017-01-25T22:53:51+0000' | timeago}} • Announcement

$MCK reported flat 3Q17 earnings results. Net income during the quarter was $633MM compared to $634 during 3Q16. Diluted EPS rose 4.3% YoverY to $2.85 from $2.73 due to the lower weighted average common share. Revenues rose 5% YoverY to $50.1Bil. Excluding items, $MCK earned $3.05 per share.

$MCK {{ '2017-01-18T12:03:05+0000' | timeago}} • Announcement

$MCK finalized administrative and civil settlements to resolve U.S. Drug Enforcement Administration (DEA) and U.S. Department of Justice (DOJ) potential federal civil and administrative claims regarding its monitoring and reporting of suspicious controlled substance orders.

$MCK {{ '2016-12-29T12:00:14+0000' | timeago}} • Announcement

$MCK, which agreed to acquire Rexall Health for CAD2.9Bil in March 2016, closed that acquisition. Earlier, the company reached an agreement with the Competition Bureau of Canada for this acquisition and received approval under the Investment Canada Act. Also, $MCK appointed Domenic Pilla as CEO of McKesson Canada, effective Jan. 3, 2017.

$MCK {{ '2016-12-14T18:12:31+0000' | timeago}} • Announcement

$MCK said it signed a consent agreement with the Competition Bureau of Canada allowing it to proceed with the acquisition of Rexall Health. The transaction is expected to close as efficiently as possible subject to certain closing conditions.

$MCK {{ '2016-10-28T14:15:10+0000' | timeago}} • Announcement

$MCK's BoD declared a regular quarterly dividend of 28 cents per share on its common stock. The dividend will be payable on Jan. 2, 2017 to stockholders of record on Dec. 1, 2016.

Recent Transcripts

ORCL (Oracle Corporation)
Thursday, September 14 2017 - 9:00pm
STRM (Streamline Health Solutions, Inc.)
Thursday, September 14 2017 - 1:00pm
CSCO (Cisco Systems, Inc.)
Wednesday, August 16 2017 - 8:30pm
AMS (American Shared Hospital Services)
Thursday, August 10 2017 - 7:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
HMSY (HMS Holdings Corp.)
Friday, August 4 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
NUS (Nu Skin Enterprises Inc.)
Wednesday, August 2 2017 - 9:00pm
DOX (Amdocs Limited)
Wednesday, August 2 2017 - 9:00pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
CAH (Cardinal Health, Inc.)
Wednesday, August 2 2017 - 12:30pm
HLF (Herbalife Ltd.)
Tuesday, August 1 2017 - 9:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
HSKA (Heska Corporation)
Monday, July 31 2017 - 3:00pm
ROP (Roper Technologies, Inc.)
Monday, July 31 2017 - 12:30pm
OMCL (Omnicell, Inc.)
Thursday, July 27 2017 - 8:30pm

AlphaGraphics you may like